ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1577	National Cancer Institute	Html	en	Retinoblastoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of retinoblastoma in children.	cancer treatment 0.489298 body 0.467706 type 0.422666 PDQ cancer information 0.456409 clinical trial search 0.418893 retinoblastoma 0.865388 retinoblastoma treatment centers 0.451209 systemic chemotherapy 0.574478 regular eye exams 0.443823 clinical trials 0.855386 recurrent intraocular retinoblastoma 0.415908 high-dose chemotherapy 0.465125 cancer information summary 0.42823 clinical trial 0.564195 patients 0.408556 eye 0.840016 radiation therapy 0.862799 optic nerve 0.459799 child 0.430789 heritable form 0.409154 treatment 0.773723 bilateral intraocular retinoblastoma 0.418197 heritable retinoblastoma 0.466245 Nonheritable retinoblastoma 0.41969 cancer cells 0.573196	extraocular retinoblastoma 0.479879 retinoblastoma cells 0.416299 Intravitreal chemotherapy 0.407999 treatment clinical trials 0.426091 RB1 gene 0.435629 National Cancer Institute 0.44282 spinal cord 0.437008 intraocular retinoblastoma 0.468181 effects cancer treatment 0.415229 new treatment 0.441768 artery infusion chemotherapy 0.538311 external-beam radiation therapy 0.642309 recurrent extraocular retinoblastoma 0.414269 ophthalmic artery infusion 0.504849 metastatic retinoblastoma 0.407008 trilateral retinoblastoma 0.466869 bone marrow 0.434989 cancer clinical trials 0.449674 cavitary retinoblastoma 0.436997 stem cell rescue 0.535096 tumor 0.495126 retinoblastoma spreads 0.40533 internal radiation therapy 0.438773 cancer 0.972687	CLICK HERE
1627	National Cancer Institute	Html	en	Liver (Hepatocellular) Cancer Prevention (PDQ®)–Patient Version	Hepatitis B and C, cirrhosis, and aflatoxin (poison from certain foods) are important risk factors for liver cancer. Learn about all of the risk factors for liver cancer and how to prevent liver cancer in this expert-reviewed summary.	hepatocellular) cancer: 0.61402 cancer risk factors 0.453697 Cancer prevention 0.626716 cancer prevention trials 0.490017 Hepatitis viruses 0.484698 hepatitis G virus 0.482783 cancer protective factor 0.439442 hepatitis B virus 0.48738 hepatitis infection 0.475638 hepatitis B. 0.524229 protective factors 0.458515 following PDQ summaries 0.446108 Cancer Information Service 0.428793 PDQ cancer information 0.628691 hepatitis E virus 0.48361 prevention clinical trials 0.441049 acute hepatitis 0.480938 Hepatitis A vaccine 0.480499 Prevention Editorial Board 0.442759 hepatitis C virus 0.486051 National Cancer Institute 0.524466 clinical trials 0.620519 especially hepatitis 0.473486	cancer information summary 0.538122 risk factors 0.559595 breast cancer prevention 0.419616 hepatitis virus 0.531251 hepatitis B vaccine 0.480451 liver cancer prevention 0.489862 Cancer Care page 0.416878 PDQ database 0.39653 hepatitis C. 0.481259 cancer risk factor 0.462005 hepatitis 0.804007 NCI’s PDQ 0.403154 PDQ summary 0.417038 hepatitis A virus 0.488307 NCI PDQ cancer 0.479454 chronic hepatitis 0.527021 cancer clinical trials 0.440605 hepatitis D virus 0.484344 hepatitis B infection 0.473174 healthy liver tissue 0.433816 cancer information summaries 0.436678 comprehensive cancer information 0.436454 cancer 0.929112	CLICK HERE
1740	National Cancer Institute	Html	en	Hair Dyes and Cancer Risk	A fact sheet that reviews research about the possibility of a connection between personal hair dye use and cancer.	female breast cancer 0.364162 hair dye 0.94208 hair dye products 0.547022 hair dyes 0.824788 Kupelnick B. Personal 0.356107 Modern hair dyes 0.445893 C. Personal hair 0.381701 case-control study 0.408793 bladder cancer 0.729938 consumer exposure study 0.34979 permanent hair dye 0.484417 increased risk 0.395633 case-control studies 0.347772 bladder cancer risk 0.47239 Montes-Martinez A. Personal 0.354703 IARC Working Group 0.350056 permanent hair dyes 0.502056 MR. Bladder cancer 0.389163 American Journal 0.365295 temporary hair dyes 0.442658 hair coloring products 0.388447 currently marketed products 0.354822 leukemia/small lymphocytic lymphoma 0.349931 colorless dye 0.417079 A. Bladder cancer 0.391043	Cancer Epidemiology Biomarkers 0.364493 International Journal 0.379963 public health impact 0.349406 black permanent dyes 0.401612 color dyes 0.375257 Personal permanent hair 0.383955 United States 0.383182 adult acute leukemia 0.391088 non-Hodgkin lymphoma 0.350907 conflicting results 0.412706 bladder cancer study 0.39321 earlier hair dyes 0.42871 personal hair dye 0.756765 studies 0.389653 bladder-cancer risk 0.359564 public health 0.351318 dark-colored dyes 0.399225 follicular lymphoma 0.348182 recent dye formulations 0.42394 aromatic amines 0.360034 hair dye formulations 0.474224 specific NHL subtypes 0.351636 hair dye users 0.497516 et al 0.482744	CLICK HERE
1761	National Cancer Institute	Html	en	HIV Infection and Cancer Risk	A fact sheet that describes the increased risk of certain types of cancer by people infected with HIV.	HIV-infected persons 0.508754 Interagency HIV Study 0.502379 lung cancer 0.484047 B-cell non-Hodgkin lymphoma 0.458276 J. Hepatocellular cancer 0.468864 non-HIV cancer risk 0.494393 Cancer Specimen Resource 0.469635 HIV-infected populations 0.478653 AIDS Malignancy 0.457277 cervical cancer 0.693342 Cancer Match Study 0.479104 current HIV treatment 0.516027 cause liver cancer 0.489672 Shiels MS 0.582975 recent cancer trends 0.457251 Cancer Epidemiology 0.46223 cancers 0.670125 human immunodeficiency virus 0.500937 HIV-infected population 0.54327 HIV-infected people 0.947346 United States 0.521772 non–AIDS-defining cancers 0.549624 antiretroviral therapy 0.544479 non-Hodgkin lymphoma 0.547712 poorer cancer survival 0.482973	general population 0.519659 A. HIV infection 0.48948 Kaposi sarcoma 0.627254 anal cancers 0.515539 HIV-associated cancers 0.517566 AIDS-defining cancers 0.457988 National Cancer Institute 0.47979 substantially higher risk 0.462943 Silverberg MJ 0.555726 Hodgkin lymphoma 0.483616 AIDS Cancer Clinical 0.500517 higher risk 0.566781 HIV-infected individuals 0.743448 HIV-related cancers 0.456193 anal cancer 0.625604 HIV-infected women 0.50457 oral cavity/pharynx cancer 0.497269 cancer risk 0.617858 et al 0.549092 New England Journal 0.468444 cancer 0.93948 liver cancer 0.56236 appropriate cancer treatment 0.491194 HIV infection 0.611339	CLICK HERE
1814	National Cancer Institute	Html	es	Tratamiento del cáncer de esófago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de esófago.	potentially operable carcinoma 0.227364 Compton CC 0.235729 gastric cardia carcinomas 0.224835 oesophageal cancer 0.276104 M0 TX 0.378744 largo plazo 0.224774 7th ed 0.235623 Oesophageal Cancer Followed 0.223828 Symptomatic gastroesophageal reflux 0.225069 ecografía endoscópica 0.322801 Estados Unidos 0.43962 mortalidad perioperatoria 0.229531 Natl Cancer Inst 0.232717 estadificación tnm 0.223626 La incidencia 0.230541 estadio iv 0.258573 M0 T2 0.809899 tumor.ampliar cáncer 0.321047 M0 T1 0.972287 Lerut A 0.228355 M0 T3 0.670603 estadio ib 0.273395 estadio ia 0.270617 células escamosas versus 0.290657 Van Cutsem E 0.252346	Estadio Grado Localización 0.256738 mucosa esofágica distal 0.27828 tumor.ampliar adenocarcinoma 0.241411 Cancer Staging Manual 0.279268 iia 1-x superior 0.228 Thorac Cardiovasc Surg 0.318859 estadio iiia 0.354448 PDQ Tratamiento 0.239147 New York 0.233171 invasive surgical staging 0.223534 estadio iiic 0.343305 estadio iia 0.319628 Cancer treatment 0.223659 Clin Oncol 0.262378 medio t2–3 0.237546 Byrd DR 0.234186 M1 TX 0.23325 American Joint Committee 0.2654 Thorac Surg 0.250251 M0 Tis 0.325056 positron emission tomography 0.377883 Am Coll Surg 0.230102 M0 T4a 0.550107 AJCC Cancer Staging 0.282666	CLICK HERE
1835	National Cancer Institute	Html	es	Tratamiento del mesotelioma maligno (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer del mesiotelioma maligno.	advanced malignant 0.116955 Cancer Res Clin 0.143881 unresectable malignant mesothelioma 0.113438 malignant mesothelioma previously 0.112719 Lung Cancer Study 0.118498 Leukemia Group 0.124194 Venkatraman E 0.115582 therapy with induction 0.114339 Antman KH 0.111559 Vogelzang NJ 0.12467 systemic chemotherapy 0.119496 patients with mesothelioma 0.113972 Thorac Oncol 0.117632 malignant mesothelioma 0.548307 with induction chemotherapy 0.120652 cisplatino versus 0.116229 Res Clin Oncol 0.141606 mesotelioma sarcomatoide 0.113237 intraperitoneal chemotherapy as 0.127133 patients with 0.17944 Union Against Cancer 0.114155 chemotherapy followed 0.119996 cisplatin-based intraperitoneal chemotherapy 0.127819 Lung Cancer 0.119323 multimodality approach 0.111112	PDQ Síndromes cardiopulmonares 0.116256 pleural maligno difuso 0.117211 Rusch VW 0.116274 patients with malignant 0.151958 National Cancer Institute 0.112603 induction chemotherapy followed 0.11661 Thorac Cardiovasc Surg 0.13604 Trimodality therapy with 0.114339 malignant pleural mesothelioma 0.977908 malignant peritoneal mesothelioma 0.154368 Clin Oncol 0.739133 extrapleural pneumonectomy 0.187603 diagnosed pleural mesothelioma 0.118912 DeCamp M 0.110451 pleural mesothelioma using 0.118896 cisplatino pemetrexed 0.111439 chemotherapy as treatment 0.13551 treated patients with 0.113408 advanced malignant mesothelioma 0.112494 Mentzer SJ 0.110243 European Organization 0.127591 Thorac Surg 0.114739 diffuse malignant mesothelioma 0.138575 pleural malignant 0.119345	CLICK HERE
1964	National Cancer Institute	Html	es	Tratamiento del cáncer de uretra (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de uretra.	uretra distal 0.983772 siguientes procedimientos 0.582434 siguientes elementos 0.524145 siguientes aspectos 0.522333 proximal.ampliar anatomía 0.514787 enfermedad.ampliar ureteroscopía 0.522025 Physician Data Query 0.500221 VPH tipo 0.523805 túbulos renales 0.527052 siguientes tipos 0.512788	libre uso 0.498555 media pulgada 0.51317 rayos x 0.553518 sistema urinario masculino 0.542122 pequeño rulo 0.511879 Cancer Institute 0.497836 siguientes riesgos 0.497881 realidad células 0.521213 pelvis renal 0.642604 Institutos Nacionales 0.50085	CLICK HERE
3678	National Cancer Institute	Html	en	NCI Outstanding Investigator Award Recipients	Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.	Professor 0.818386 cancer cell fate 0.872486 tumor interstitial fluid 0.811256 Institution 0.848074 brain cancer stem 0.81847 Salk Institute Cancer 0.836669 cancer therapy 0.800257 ccRCC tumor metabolism 0.813028 cancer stem cell 0.87789 Harvard Medical School 0.902146 Institute Cancer Center 0.918217 Mount Sinai Cancer 0.82427 interactive research areas 0.831532 new therapeutic targets 0.831101 Tisch Cancer Institute 0.836924 tumor suppressor functions 0.808451 Cell Biology Laboratory 0.802354 clinical cancer research 0.915827 Hopkins University School 0.800509 Medical Research 0.805386 molecular mechanisms 0.847735 human cancer metabolism 0.844789 kidney cancer subtype 0.813888 Cancer Research Program 0.87416 mouse models 0.817082	leukemia cell metabolism 0.821118 Cancer Research Center 0.897578 cancer cell metabolism 0.867114 cancer cells 0.87218 Stem Cell Biology 0.799482 distinct cell types 0.801724 Anderson Cancer Center 0.828569 cancer research 0.977431 Adolphus Pfeiffer Professor 0.801659 HGG cancer cell 0.848375 tumor suppressor gene 0.80279 Center Research Institute 0.861555 Title 0.835958 Cancer Society Research 0.870208 Stem Cell Research 0.847258 Cell Biology 0.815108 tumor microenvironment signals 0.812505 Cancer Imaging Research 0.895426 Cell Biology Department 0.805035 acute lymphoblastic leukemia 0.839865 Bakar Distinguished Professor 0.809836 Wistar Institute Cancer 0.864712 M. Temin Professor 0.801808 tumor microenvironment 0.889603	CLICK HERE
16845	National Cancer Institute	Html	en	Masimo Corporation — Mechanical Drugs: Harnessing Cancer Aggressiveness to Overcome Its Resistance	Developing a new therapeutic approach to triple negative breast cancer (TNBC) which is based on intracellular mechanical impact generated by plasmonic nanobubbles.	synergy 0.336432 gold nanoparticles 0.550066 liposome-encapsulated drugs 0.504619 M.D. 0.377619 intracellular gold nanoparticle 0.766413 project team 0.493532 chemotherapy 0.340382 bubble generation threshold 0.657269 short laser pulse 0.734768 Ph.D. 0.365843 TNBC 0.333035 higher selectivity 0.504113 goal 0.33328 accumulation 0.342776 absorption 0.340473 negative breast cancer 0.692185 nanomaterials 0.340596 Co-Investigators 0.334002 plasmonic nanobubbles 0.543572 Principal Investigators 0.516256 Resistance 0.336765 radiotherapy 0.347319 Masimo Corporation 0.532528 Mechanical Drugs 0.555482 EGFR-expressing cancer cells 0.691288	Vladimir Torchilin 0.519417 optical energy 0.499453 Ph.D 0.376534 larger gold clusters 0.685801 mechanical impact 0.858201 modalities 0.337622 radiation oncology 0.496973 Mien-Chie Hung 0.526833 nanobubble-disrupted liposomes 0.520675 Cancer Aggressiveness 0.580782 normal cells 0.511798 laser pulse 0.92023 Gillenwater 0.333958 Jack Phan 0.537018 host cell 0.497762 non-stationary vapor bubbles 0.750751 gold nanoclusters 0.536739 new therapeutic approach 0.68193 Nie 0.367583 Dmitri Lapotko 0.533767 molecular / cell 0.487681 low-energy laser pulse 0.711917 intracellular mechanical impact 0.751573 cancer biology 0.50282	CLICK HERE
16867	National Cancer Institute	Html	null	Cómo encontrar a un doctor o un establecimiento de tratamiento si usted tiene cáncer	Hoja informativa que ofrece sugerencias para escoger a un médico y un establecimiento para el tratamiento del cáncer.			CLICK HERE